OncoMatch/Clinical Trials/NCT05055908

Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors

Is NCT05055908 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Pemetrexed plus Pembrolizumab and Pembrolizumab for lung cancer.

Phase 3RecruitingHunan Province Tumor HospitalNCT05055908Data as of May 2026

Treatment: Pemetrexed plus Pembrolizumab · Pembrolizumab · Pemetrexed — The purpose of the study is to find some biomarkers to predict the the adverse events of Immune Checkpoint Inhibitors monotherapy or plus platinum based chemotherapy in lung cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Prior therapy

Must have received: checkpoint inhibitor

Lab requirements

Blood counts

adequate bone marrow hematopoiesis

Kidney function

adequate organ function

Liver function

adequate organ function

Adequate bone marrow hematopoiesis and organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify